Jiawei Zuojin pills combined with rabeprazole sodium in treatment of patients with gastroesophageal reflux disease of liver-stomach depression and heat type
Objective To explore the clinical efficacy and safety of Jiawei Zuojin pills combined with rabeprazole sodium in the treatment of patients with gastroesophageal reflux disease of the liver-stomach depression and heat type.Methods One hundred and twenty patients with gastroesophageal reflux disease of the liver-stomach depression and heat type who were admitted to Department of Spleen,Stomach,and Liver Diseases,Yan'an Hospital of Traditional Chinese Medicine from June 2021 to June 2023 were selected for the randomized controlled trial,and were divided into a control group and a combined treatment group by the random number table method,with 60 cases in each group.There were 28 males and 32 females in the control group;they were(42.32±5.42)years old;their disease course was(3.51±0.87)years;their body mass index was(23.52±1.91)kg/m2.There were 31 males and 29 females in the combined treatment group;they were(43.88±6.17)years old;their disease course was(3.92±1.04)years;their body mass index was(24.05±0.47)kg/m2.The control group were treated with rabeprazole sodium,and the combined treatment group with Jiami Zuogin pillsand rabeprazole sodium,for 8 weeks.The clinical efficacies,endoscopic scores,scores of clinical symptoms of traditional Chinese medicine,and levels of serum gastrointestinal hormones[gastrin(Gas),motilin(MTL),vasoactive intestinal peptide(VIP),and somatostatin(SS)],and scores of Self-Rating Anxiety Scale(SAS)and Self-Rating Depression Scale(SDS)before and after the treatment,and incidences of adverse reactions were compared between the two groups by t and x2 tests.Results After the treatment,the endoscopic score in the combined treatment group was lower than that in the control group[(0.87±0.23)vs.(1.31±0.58);P＜0.05].The total effective rates of the combined treatment group and the control group were 93.33％(56/60)and 78.33％(47/60),respectively,with a statistical difference(x=4.312,P=0.009).After the treatment,the scores of post-sternal burning pain,acid reflux,thoracic and hypochondriac pain,gastrointestinal and epigastric pain,epigastric distension,belching or regurgitation,and irritability in the combined treatment group were lower than those in the control group[(1.49±0.65)vs.(3.51±0.91),(1.34±0.27)vs.(2.64±0.87),(0.34±0.16)vs.(0.51±0.21),(0.24±0.11)vs.(0.46±0.12),(0.31±0.14)vs.(0.57±0.33),(0.19±0.17)vs.(0.32±0.11),and(0.63±0.24)vs.(1.05±0.68);all P＜0.05];there was no statistical difference in the score of being hungery easily between the two groups(P＞0.05).After the treatment,the levels of GAS,MTL,VIP,and SS in the combined treatment group were(126.11±11.52)ng/L,(102.66±8.16)ng/L,(45.88±7.44)ng/L,and(9.01±2.17)ng/L,and those in the control group were(105.63±10.21)ng/L,(84.33±7.17)ng/L,(53.52±6.23)ng/L,and(15.43±3.61)ng/L,with statistical differences(all P＜0.05).After the treatment,the scores of SAS and SDS in the combined treatment group were lower than those in the control group[(30.66±10.29)vs.(41.31±8.55)and(31.44±8.19)vs.(38.12±11.28);both P＜0.05].The incidence of adverse reactions in the combined treatment group was 6.67％(4/60),and that of the control group was 8.33％(5/60),with no statistical difference(x2=0.531,P=0.637).Conclusion Jiawei Zuojin pills combined with rabeprazole sodium in the treatment of patients with gastroesophageal reflux disease of the liver-stomach depressive heat type is effective and safe.
Gastroesophageal reflux diseaseJiawei Zuojin pillsRabeprazole sodiumLiver-stomach depression and heat syndrome
万方数据
维普
